v3.26.1
Capital Stock and Earnings Per Share
 3 Months Ended
May 02, 2026
Equity [Abstract]  
Capital Stock and Earnings Per Share Capital Stock and Earnings Per Share
Capital Stock
In February 2026, the Company announced that its Board of Directors had approved a new stock repurchase program that authorizes the repurchase of up to an additional $3.0 billion of TJX common stock from time to time. Under this program and previously announced programs, TJX had approximately $3.5 billion available for repurchase as of May 2, 2026.
The following table provides share repurchases, excluding applicable excise tax:
Thirteen Weeks Ended
In millionsMay 2,
2026		May 3,
2025
Total number of shares repurchased and retired3.8 5.1 
Total cost
$604 $613 
All shares repurchased under the stock repurchase programs have been retired. These expenditures were funded by cash on hand and cash generated from operations.
Earnings Per Share
The following table presents the calculation of basic and diluted earnings per share:
 Thirteen Weeks Ended
Amounts in millions, except per share amountsMay 2,
2026		May 3,
2025
Basic earnings per share:
Net income
$1,332 $1,036 
Weighted average common shares outstanding for basic earnings per share calculation
1,106 1,118 
Basic earnings per share
$1.20 $0.93 
Diluted earnings per share:
Net income
$1,332 $1,036 
Weighted average common shares outstanding for basic earnings per share calculation
1,106 1,118 
Assumed exercise/vesting of stock options and awards14 14 
Weighted average common shares outstanding for diluted earnings per share calculation
1,120 1,132 
Diluted earnings per share
$1.19 $0.92 
Cash dividends declared per share$0.480 $0.425 
The weighted average common shares for the diluted earnings per share calculation excludes the impact of outstanding stock options if the assumed proceeds per share of the option is in excess of the average price of TJX’s common stock for the related fiscal periods. Such options are excluded because they would have an antidilutive effect. There were 3 million and 4 million antidilutive options excluded for the thirteen weeks ended May 2, 2026 and May 3, 2025, respectively.